# COVID-19 Assay Data

We are making our efforts to collect the COVID-19 experimantal results from various resouces with assays tested using SARS-COV-2 materials. We will update this dataset continuously to provide more information to help your research combat the disease. 


|  ﻿ID  | Drug_name  | Experimental_activities  | Measurement  | Value  | Unit  | Cytotoxicity(CC-50)  | SI  | Reference  | 
| ---- | --- | --- | --- | --- | --- | --- | --- | --- | 
|  1  | Remdesivir  | SARS-CoV-2 inhibition  | EC50  | 0.77  | μM  | >100  | >129.87  | [1](https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w)  | 
|  2  | Chloroquine  | SARS-CoV-2 inhibition  | EC50  | 1.13  | μM  | >100  | >88.5  | [1](https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w)  | 
|  3  | Nitazoxanide  | SARS-CoV-2 inhibition  | EC50  | 2.12  | μM  | 35.53  | >16.76  | [1](https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w)  | 
|  4  | Chlorpromazine Hydrochloride  | SARS-CoV-2 inhibition  | IC50  | 4.03  | μM  | 11.88  | 2.94  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  5  | Amodiaquin Dihydrochloride Dihydrate  | SARS-CoV-2 inhibition  | IC50  | 4.94  | μM  | 34.42  | 6.97  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  6  | CVL218  | SARS-CoV-2 inhibition  | EC50  | 5.12  | μM  | 91.05  | 17.78  | [2](https://www.biorxiv.org/content/10.1101/2020.03.11.986836v1.abstract)  | 
|  7  | Imatinib Mesylate  | SARS-CoV-2 inhibition  | IC50  | 5.32  | μM  | >30.86  | >5.80  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  8  | Fluspirilene  | SARS-CoV-2 inhibition  | IC50  | 5.32  | μM  | 30.33  | 5.71  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  9  | Amodiaquin Hydrochloride  | SARS-CoV-2 inhibition  | IC50  | 5.64  | μM  | >38.63  | >6.84  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  10  | Triparanol  | SARS-CoV-2 inhibition  | IC50  | 6.41  | μM  | 21.21  | 3.31  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  11  | Clomipramine Hydrochloride  | SARS-CoV-2 inhibition  | IC50  | 7.59  | μM  | >29.68  | >3.91  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  12  | Thiethylperazine Maleate  | SARS-CoV-2 inhibition  | IC50  | 8.02  | μM  | 18.37  | 2.29  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  13  | Mefloquine Hydrochloride  | SARS-CoV-2 inhibition  | IC50  | 8.06  | μM  | 18.53  | 2.3  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  14  | Fluphenazine Dihydrochloride  | SARS-CoV-2 inhibition  | IC50  | 8.98  | μM  | 20.02  | 2.23  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  15  | Tamoxifen Citrate  | SARS-CoV-2 inhibition  | IC50  | 8.98  | μM  | 37.96  | 4.23  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  16  | Promethazine Hydrochloride  | SARS-CoV-2 inhibition  | IC50  | 10.44  | μM  | >42.59  | >4.08  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  17  | Hydroxychloroquine Sulfate  | SARS-CoV-2 inhibition  | IC50  | 11.17  | μM  | >50  | >4.48  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  18  | Toremifene Citrate  | SARS-CoV-2 inhibition  | IC50  | 11.3  | μM  | 20.51  | 1.81  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  19  | Terconazole Vetranal  | SARS-CoV-2 inhibition  | IC50  | 16.14  | μM  | 41.46  | 2.57  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  20  | Benztropine Mesylate  | SARS-CoV-2 inhibition  | IC50  | 17.79  | μM  | >50  | >2.81  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  21  | Nafamostat  | SARS-CoV-2 inhibition  | EC50  | 22.5  | μM  | >100  | >4.44  | [1](https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w)  | 
|  22  | Chloroquine Phosphate  | SARS-CoV-2 inhibition  | IC50  | 46.8  | μM  | >50  | >1.07  | [3](https://www.biorxiv.org/content/10.1101/2020.03.25.008482v1)  | 
|  23  | Favipiravir  | SARS-CoV-2 inhibition  | EC50  | 61.88  | μM  | >400  | >6.46  | [1](https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w)  | 
|  24  | Penciclovir  | SARS-CoV-2 inhibition  | EC50  | 95.96  | μM  | >400  | >4.17  | [1](https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w)  | 
|  25  | Ribavirin  | SARS-CoV-2 inhibition  | EC50  | 109.5  | μM  | >400  | >3.65  | [1](https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w)  | 

